JNJ-54179060
Phase 1Small molecule
Johnson & JohnsonJNJ-54179060 is one of 23 small molecule programs targeting Leukemia, Myeloid, Acute. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Leukemia, Myeloid, Acute
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 3
Peony
TakedaPhase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Cytosar
TevaPhase 2
Fludara
SanofiPhase 2
Trexall
Alnylam PharmaceuticalsPhase 2
Bleximenib
Johnson & JohnsonPhase 3
Revuforj
SSyndax Pharmaceuticals
Phase 2
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
ORCA-T
OOrca Biosystems, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JNJ-54179060. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company